Drug Trial Radar · NCT03778047
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Feb 7, 2018
Primary completion
Oct 24, 2018
Study completion Aug 28, 2019
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and related changes after drug switch in Chinese patients with metastatic castration-resistant prostate cancer. The study primary objective is to evaluate the pharmacokinetic characteristics of enzalutamide in Chinese patients with mCRPC.
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
EnzalutamideDrug
oral
HC1119Drug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum drug concentration(Cmax)Time frame: From the first dose of the study drug to 12 weeks after dose
- Time of maximum drug concentration(Tmax)Time frame: From the first dose of the study drug to 12 weeks after dose
- Area under curve from time 0 to 24h (AUC0-24h)Time frame: From the first dose of the study drug to 12 weeks after dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Ethics Committee of Hunan Cancer Hospital
Changsha, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.